News By Tag
News By Location
Drug Safety Executive Council Announces Inaugural Technology Innovation Award Winner
The Drug Safety Executive Council (DSEC) today announced that VivaQuant™ is the winner of the Technology Innovation Award as determined by a DSEC member vote.
Each quarter organizations submit scientific posters featuring novel technologies to DSEC’s virtual poster gallery. Only four posters are nominated as finalists by Dr. Jack Reynolds, Chairman of the DSEC Advisory Board.
“Technology innovation is what will drive better decision making in drug safety, “ said Reynolds. “We are fortunate to have received dozens of posters detailing extremely exciting, novel platforms. Nominating only four posters was extremely challenging. I am sure that determining the ‘most innovative’ technology proved to be difficult for our members.”
The Q2, 2011 winning poster is entitled “A Novel Algorithm for Highly Automated Measurement of QT” and features VivaQuant’s Multi-Domain Signal ProcessingTM (MDSP) technology and it received 70% of the member votes submitted. The VivaQuant platform provides highly automated measurements of beat-to-beat QT intervals from ambulatory ECG recordings where noise and artifact have traditionally been a limitation to widespread implementation. The algorithm employs a novel technology that suppresses noise inside the ECG pass-band by up to 85% without distorting the signal morphology.
“I want to thank DSEC and its members for selecting VivaQuant for the Technology Innovation award and I am happy to accept the award on behalf of VivaQuant,” said, Dr. Marina Brockway, Chief Technology Officer, VivaQuant.
VivaQuant plans to commercialize a line of products and services based upon the MDSP signal processing platform, the foundation of the QT algorithm described in its award-winning poster. The first of these is for highly automated arrhythmia analysis, to be released later this year.
About The Drug Safety Executive Council (DSEC)
DSEC is a peer membership of 2,000 drug safety leaders with the common objective of advancing the development of better and safer medicines. Membership is limited to employees of companies developing small and large molecule pharmaceuticals. DSEC also manages a Technology Evaluation Consortium that qualifies novel, preclinical safety platforms. DSEC is owned and operated by Cambridge Healthtech Associates (CHA). Learn more at www.drugsafetycouncil.org or www.chacorporate.com
VivaQuant is engaged in providing innovative tools that help researchers more accurately and efficiently extract and quantify information from physiological signals. VivaQuant’s seasoned product and technology development staff brings more than 85 years of aggregate experience in life science tools, algorithm development, and medical device design to bear on finding creative solutions to the challenges faced by life science researchers. For more information go to: www.vivaquant.com.
Manager, Member Services
President and CEO